85/100 · Critical
Manufactured by Yiling Pharmaceutical, Inc.
Serious Adverse Reactions Common with Ciprofloxacin Tablets
160,486 FDA adverse event reports analyzed
Last updated: 2026-05-12
CIPROFLOXACIN TABLETS is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Yiling Pharmaceutical, Inc.. Based on analysis of 160,486 FDA adverse event reports, CIPROFLOXACIN TABLETS has a safety score of 85 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for CIPROFLOXACIN TABLETS include FATIGUE, ACUTE KIDNEY INJURY, PAIN, DIARRHOEA, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CIPROFLOXACIN TABLETS.
Ciprofloxacin Tablets has a safety concern score of 85 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 160,486 adverse event reports for this medication, which is primarily manufactured by Yiling Pharmaceutical, Inc..
The most commonly reported adverse events include Fatigue, Acute Kidney Injury, Pain. Of classified reports, 88.3% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Serious adverse reactions, including acute kidney injury and renal failure, are frequently reported.
Pain and fatigue are among the most common complaints, affecting a significant portion of users. Drug interactions and ineffective drug performance are also notable concerns.
Patients taking Ciprofloxacin Tablets should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Ciprofloxacin tablets can cause serious kidney-related issues and should be used with caution, especially in patients with pre-existing kidney conditions. Drug interactions are also a concern, and patients should inform their healthcare providers of This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Ciprofloxacin Tablets received a safety concern score of 85/100 (high concern). This is based on a 88.3% serious event ratio across 69,512 classified reports. The score accounts for 160,486 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 35,042, Male: 28,136, Unknown: 275. The most frequently reported age groups are age 65 (1,506 reports), age 67 (1,130 reports), age 66 (1,102 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 69,512 classified reports for CIPROFLOXACIN TABLETS:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Ciprofloxacin tablets can cause serious kidney-related issues and should be used with caution, especially in patients with pre-existing kidney conditions. Drug interactions are also a concern, and patients should inform their healthcare providers of
If you are taking Ciprofloxacin Tablets, here are important things to know. The most commonly reported side effects include fatigue, acute kidney injury, pain, diarrhoea, nausea. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Inform your healthcare provider about any pre-existing kidney conditions before starting Ciprofloxacin tablets. Report any new or worsening symptoms to your healthcare provider promptly. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA closely monitors the safety of Ciprofloxacin tablets, and any new or worsening symptoms should be reported to healthcare providers immediately. Regular monitoring of kidney function is recommended for patients taking this medication.
The FDA has received approximately 160,486 adverse event reports associated with Ciprofloxacin Tablets. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Ciprofloxacin Tablets include Fatigue, Acute Kidney Injury, Pain, Diarrhoea, Nausea. By volume, the top reported reactions are: Fatigue (4,227 reports), Acute Kidney Injury (4,106 reports), Pain (4,104 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Ciprofloxacin Tablets.
Out of 69,512 classified reports, 61,371 (88.3%) were classified as serious and 8,141 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Ciprofloxacin Tablets break down by patient sex as follows: Female: 35,042, Male: 28,136, Unknown: 275. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Ciprofloxacin Tablets adverse events are: age 65: 1,506 reports, age 67: 1,130 reports, age 66: 1,102 reports, age 69: 1,092 reports, age 62: 1,091 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Ciprofloxacin Tablets adverse event reports is Yiling Pharmaceutical, Inc.. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Ciprofloxacin Tablets include: Arthralgia, Chronic Kidney Disease, Drug Ineffective, Drug Hypersensitivity, Off Label Use. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Ciprofloxacin Tablets to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Ciprofloxacin Tablets has a safety concern score of 85 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Serious adverse reactions, including acute kidney injury and renal failure, are frequently reported.
Key safety signals identified in Ciprofloxacin Tablets's adverse event data include: Acute kidney injury and renal failure are key safety signals.. Pain and fatigue are frequent and serious adverse reactions.. Drug ineffectiveness and hyper-sensitivity reactions are significant.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Ciprofloxacin tablets can cause serious kidney-related issues and should be used with caution, especially in patients with pre-existing kidney conditions. Drug interactions are also a concern, and patients should inform their healthcare providers of Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Ciprofloxacin Tablets.
Inform your healthcare provider about any pre-existing kidney conditions before starting Ciprofloxacin tablets. Report any new or worsening symptoms to your healthcare provider promptly.
Ciprofloxacin Tablets has 160,486 adverse event reports on file with the FDA. Pain and fatigue are among the most common complaints, affecting a significant portion of users. The volume of reports for Ciprofloxacin Tablets reflects both the drug's usage level and the vigilance of the reporting community.
The FDA closely monitors the safety of Ciprofloxacin tablets, and any new or worsening symptoms should be reported to healthcare providers immediately. Regular monitoring of kidney function is recommended for patients taking this medication. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
The following drugs share commonly reported adverse reactions with CIPROFLOXACIN TABLETS:
Drugs related to CIPROFLOXACIN TABLETS based on therapeutic use, drug class, or shared indications: